



Research Article

Urinary C-Peptide Excretion for Diabetic Treatment in Low Carbohydrate Diet (LCD)

Hiroshi Bando^{1,2*}, Koji Ebe^{2,3}, Tetsuo Muneta^{2,4}, Masahiro Bando⁵, Yoshikazu Yonei⁶

Affiliation

¹Tokushima University/Medical Research, Tokushima, Japan

²Takao Hospital, Kyoto, Japan

³Low Carbohydrate Diet Promotion Association, Kyoto, Japan

⁴Muneta Maternity Clinic, Chiba, Japan

⁵Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan

⁶Anti-Aging Medical Research Center, Graduate School of Life and Medical Sciences, Doshisha University, Kyoto, Japan

*Corresponding author: Hiroshi Bando, Tokushima University/Medical Research, Nakashowa 1-61, Tokushima 770-0943 Japan Tel: +81-90-3187-2485, E-mail: pianomed@bronze.ocn.ne.jp

Citation: Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Urinary C-Peptide Excretion for Diabetic Treatment in Low Carbohydrate Diet (LCD) (2018) Journal of Obesity and Diabetes 1: 13-18.

Received: Jan 08, 2018

Accepted: Jan 22, 2018

Published: Jan 26, 2018

Copyright: © 2018 Bando H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Arguments have continued about Low Carbohydrate Diet (LCD) and Calorie Restriction (CR). Authors have reported clinical research of LCD and Morbus (M) value.

Subjects and Methods: Subjects enrolled are 84 patients with Type 2 diabetes mellitus (T2DM), 60.9 ± 10.9 years. The protocol were as follows: 1) CR diet on day 1, 2 with 60% carbohydrates, and LCD on day 3-14 with 12% carbohydrates, 2) Daily profile of blood glucose 7 times a day on day 2 (CR) and day 4 (LCD), 3) urinary C-Peptide radioimmunoassay (u-CPR) excretion, 4) M value calculation, 5) investigation of these data with correlation.

Results: Subjects were classified into 4 groups according to M value, which were .4–21, 23–66, 29–192, 200–728, respectively. HbA1c value was 6.2, 8.0, 7.8, 9.2 %, respectively. Blood glucose in median from day 2 to day 4 were 123 to 107 mg/dL, 164 to 130 mg/dL, 193 to 156 mg/dL, 277 to 201 mg/dL, respectively. M value in median from day 2 to 4 was 6.3 to 9, 41 to 7, 108 to 16, 367 to 88, respectively. u-CPR was 88 to 58, 53 to 35, 65 to 52, 74 to 64, respectively. There were significant correlations among among glucose, M value and u-CPR.

Discussion and Conclusion: Average glucose, M value and u-CPR decreased remarkably on day 4. As average glucose and M value were higher, decrease degree were larger. These results suggested that carbohydrate in meal would influence glucose variability in T2DM. Our data would become basic data for pathophysiological analysis of glucose variability research in the future.

Keywords: Urinary C-peptide (u-CPR); Low Carbohydrate Diet (LCD); Morbus value (M value); type 2 diabetes mellitus (T2DM); Average Glucose (AG)

Abbreviation: CPR: C-Peptide immunoreactivity, LCD: Low-Carbohydrate Diet, CR: Calorie-Restricted, T2DM: Type 2 Diabetes Mellitus, T1DM: Type 1 Diabetes Mellitus, M value: Morbus value, MAGE: Mean Amplitude of Glycemic Excursions, HOMA-R: Homeostasis model assessment-Insulin Resistance, HOMA-β: Homeostasis model assessment of β-cell function.

Introduction

For years, there has been discussions concerning Low Carbohydrate Diet (LCD) and Calorie Restriction (CR). Recent reports have showed efficacy of LCD such as randomized controlled trials, systematic review and meta-analyses [1-3].

Historically, Atkins and Bernstein originally have started LCD in western countries [4,5]. Consecutively, clinical predominance of LCD have been shown by investigators [6-9]. Furthermore, LCD has been applied widely to several diseases and impaired states, such as metabolic syndrome

Citation: Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Urinary C-Peptide Excretion for Diabetic Treatment in Low Carbohydrate Diet (LCD) (2018) Journal of Obesity and Diabetes 1: 13-18.



(Met-S), obesity, nonalcoholic fatty liver disease (NAFLD), cardiovascular disease, and so on [10-12]

On contrast, in Japan, the author have firstly introduced and reported LCD for T2DM in Japan and developed LCD in lots of opportunities [13,14]. Subsequently, we reported clinical studies concerning LCD with pathophysiological aspects [15-18].

In current study, we investigated urinary C-Peptide immunoreactivity (u-CPR) excretion in patients with Type 2 Diabetes mellitus (T2DM). Simultaneously, we measured the average glucose and Morbus (M) value, and studied the detail correlation among these biomarkers.

Subjects and Methods

In current study, the subjects included 84 patients with T2DM, which were 33 males and 51 females. They are 28-84 years old (yo) with 60.9 ± 10.9 (mean +/- SD) yo. in average, 63 yo in the median value.

Subjects were enrolled from the in-patients of the educational admission for further evaluation and treatment of T2DM. The protocol of diet therapy were as follows:

- 1) CR diet was provided on day 1 and 2, which had 60% carbohydrates, 25% lipids and 15% protein with 1400 kcal/day.
- 2) LCD was provided from 3 to 14 days, which had 12% carbohydrates, 64% lipids and 24% protein with 1400 kcal/day.
- 3) This LCD has been called “super-LCD formula” in our clinical research for LCD, which is one of the Very low-carbohydrate ketogenic diet (VLCKD) by the definitions of LCD [13-16].

Examinations included several kinds of glucose metabolism. The are 1) several basal biomarkers on admission, 2) daily profile of blood glucose 7 times a day on day 2 (CR) and day 4 (LCD), 3) u-CPR were measured on day 2 and day 4, 4) M value was calculated from blood glucose level.

Morbus (M) value

Data obtained from daily profile of blood glucose were calculated into Morbus (M) value. M value is the index which represents both blood sugar level and mean amplitude of glycemic excursions (MAGE) [19-22]. Regarding glucose variability, daily profiles of blood glucose has been measured 7 times a day, which data were calculated into average glucose and M value. M value has been proposed for researching average glucose and MAGE. This index has been calculated as a logarithmic transformation of the deviation of glycemia from an arbitrary assigned “ideal” glucose value. Clinically, ideal glucose level would be around 120 mg/dL, then M value uses 120 mg/dL for the standard level. Consequently, M value expresses both the average glucose value and the effect of glucose swings [19-22].

M value is calculated by the following formula: $M = MBS + MW$, where $MW = (\text{maximum blood glucose} - \text{minimum glucose})/20$; $MBS = \text{the mean of MBSBS}$; $MBSBS = \text{individual M-value for each blood glucose value calculated as } (\text{absolute value of } [10 \times \log(\text{blood glucose value}/120)])^3$.

$$M\text{-value} = \frac{\sum}{N} \left| M \frac{BS}{BS} \right| + W/20 \quad \text{where} \quad M \frac{BS}{BS} = \left| 10 \log \frac{PG}{120} \right|^3$$

Concerning the interpretation of M value, the standard range would be <180, borderline 180-320 and abnormal >320. Adequate sampling times a day have been argued for detail and precise evaluation of glucose variability and MAGE. Similar results were found on 7 times or 20 times of sampling per day [19,22,23]. It also revealed similar results compared with the continuous glucose monitoring (CGM) [22,24].

Statistical analyses

In this study, obtained data was represented as the mean +/- standard deviation (SD) and also represented median, quartile of 25% and 75% in biomarkers. For statistical analyses, correlation coefficients were calculated using Pearson or Spearman test of the Microsoft Excel analytical tool, which is Four steps Excel Statistics 4th edition [25]. A significance level of less than 5% was considered to be statistically significant.

Ethical Considerations

This study was conducted in compliance with the ethical principles of the Declaration of Helsinki. It was also along with Japan’s Act on the Protection of Personal Information along with the Ministerial Ordinance on Good Clinical Practice (GCP) for Drug (Ordinance of Ministry of Health and Welfare No. 28 of March 27, 1997). Ethical committee meeting was held by physician, researchers, medical staff and legal expert. Informed consent was obtained from the subjects. The study was registered with UMIN #R000031211.

Results

Subjects were classified into 4 groups according to M value. Data of M value in 4 groups were, 4–21, 23–66, 29–192, 200–728, respectively (Table 1). Each group has 21 subjects, and other results of biomarkers were shown in Table 1.

	Group 1	Group 2	Group 3	Group 4
Subjects				
age (years old)	57.7±11.1	61.4±13.3	62.4±10.3	62.4±9.0
median [25% - 75%]	59 [55-63]	65 [55-69]	65 [58-69]	65 [61-68]
M/F	12/9	5/16	6/15	10/11
number	21	21	21	21
M value				
range	4 - 21	23 - 66	29 - 192	200 - 728
data of M value	8.3±4.5	42.6±12.7	120±40	401±174
median [25% - 75%]	6.3 [5.6 - 9.2]	41 [32 - 52]	108 [89 - 151]	367 [246 - 516]
Glucose metabolism				
Fasting glucose (mg/dL)	120±20	134±21	162±33	215±33
median [25% - 75%]	114 [107 - 135]	137 [121 - 143]	163 [141 - 178]	216 [207 - 240]
Fasting IRI (μIU/mL)	12.9±8.9	7.8±4.1	6.9±5.1	4.9±2.9
median [25% - 75%]	10.6 [6.7 - 16.7]	7.5 [4.9 - 8.8]	5.6 [3.9 - 11.1]	4.1 [3.1 - 7.1]
Insulin resistance				
HOMA-R	4.1±3.6	2.6±1.4	2.9±2.6	2.8±1.7
median [25% - 75%]	3.6 [2.2 - 5.0]	2.6 [1.5 - 2.9]	2.1 [1.3 - 3.9]	2.1 [1.7 - 4.2]
HOMA-β	89±46	39±21	27±19	11±6
median [25% - 75%]	80 [56 - 131]	34 [26 - 55]	21 [12 - 46]	10 [6 - 13]
lipids metabolism				
Triglyceride (mg/dL)	124±73	130±69	125±81	170±114
median [25% - 75%]	107 [72 - 133]	101 [75 - 161]	102 [72 - 155]	163 [81 - 200]
HDL-C (mg/dL)	55±16	54±14	67±19	64±17
median [25% - 75%]	52 [48 - 57]	53 [44 - 65]	63 [56 - 82]	63 [56 - 68]
LDL-C (mg/dL)	121±42	134±39	128±33	138±41
median [25% - 75%]	113 [95 - 134]	132 [109 - 153]	129 [109 - 153]	141 [113 - 157]

Data are expressed mean standard deviation, and also median [25%-75%].

Table 1: Basal data of the subject classified into 4 groups.




Fasting blood glucose and HbA1c value increased from group 1 to group 4 in order (Figure 1). Each median value was 114, 137, 163, 216 mg/dL, and 6.2, 8.0, 7.8, 9.2%, respectively. The average glucose on day 4 was decreased from that on day 2 in 4 groups (Figure 2). Average glucose in median from day 2 to day 4 in each group was 123 to 107 mg/dL, 164 to 130 mg/dL, 193 to 156 mg/dL, 277 to 201 mg/dL, respectively.


When calculated on daily profile of blood glucose into M value, it decreased from day 2 to day 4 in group 2,3 and 4 (Figure 3). M value in median from day 2 to day 4 in each group was 6.3 to 9, 41 to 7, 108 to 16, 367 to 88, respectively.

U-CPR on day 2 and day 4 are shown in Figure 4. In each group, decreased value from day 2 to day 4 was 88 to 58, 53 to 35, 65 to 52, 74 to 64, respectively.

There is significant correlation between blood glucose in average on day 2 and day 4 ($p < 0.01$) (Figure 5a). There is significant correlation between blood glucose in average and HbA1c ($p < 0.01$) in which the regression curve showed $y = 0.02x + 4.2$ (Figure 5b).




1a: Fasting blood glucose increases from group 1 to 4.



2a: HbA1c value increases from group 1 to 4.

Figure 1: Blood glucose and HbA1c in 4 groups.



G-1 day2: Group 1 on day 2 (CR), G-4 day4: Group 4 on day 4 (LCD).

Figure 2: The changes of average blood glucose on day 2 and day 4 in 4 groups.






Figure 3: The changes of M value on day 2 and day 4 in 4 groups.




U-CPR: urinary C-peptide immunoreactivity,

Figure 4: The changes of U-CPR excretion on day 2 and day 4 in 4 groups.




5a: Correlation between blood glucose in average on day 2 and day 4.




5b: Correlation between blood glucose in average and HbA1c.

Figure 5: Correlation between blood glucose and HbA1c. Significant correlation was observed between u-CPR on day 2 (CR) and day 4 (LCD) ($p < 0.01$), in which the regression curve showed $y = 0.75x + 4.5$ (Figure 6a). There is no significant correlation of ratio of ratio for day 4 to day 2 between average glucose and u-CPR (Figure 6b).

There is significant correlation between M value on day 2 and day 4 ($p < 0.01$) (Figure 7a). There is no significant correlation of ratio of day 2 and 4 between M value and u-CPR (Figure 7b).




6a: Correlation between u-CPR on day 2 (CR) and day 4 (LCD).



6b: Correlation of ratio for day 4 to day 2 between average glucose and u-CPR.

Figure 6: Correlation of u-CPR and blood glucose.



7a: Correlation between Morbus (M) value on day 2 and day 4.



7b: Correlation of ratio of day 2 and 4 between M value and u-CPR.

Figure 7: Correlation between Morbus (M) value and u-CPR.

Discussion

Recently, fundamental and clinical research of LCD have been developed and prevalent [26,27], and we have continued research for LCD with proposal for medical practice [28-30].

In this study, we examined changes in average glucose, M value, urinary CPR in 2 days after diet changed from CR to LCD. We also investigated the correlation among these biomarkers, and clarified efficacy of LCD for the improvement of the profile of blood glucose in short period.

M value has been useful marker that would evaluated elevated blood glucose and increased MAGE. In this

diabetic research field, we have continued to study the detail of glucose variability using M value [18,30,31].

As for current study, we divided into 4 groups according to M value. Group 1 was mild, and group 4 was severe in degree of diabetes. In Groups 2, 3 and 4, mean glucose and M values clearly decreased from day 2 to 4. On contrast, group 1 includes mild diabetes or pre-diabetic subjects. In other words, it seems that blood glucose and HbA1c are close to normal people, and the insulin secretion ability is preserved proportionally.

In group 1, blood sugar in median decreased from 123 to 107 mg/dL, and u-CPR decreased remarkably from 88 to 55 mg/day. For meal protocols, CR for day 1, 2. and LCD for day 3,4 were provided. In comparison of day 2 and day 4, the carbohydrate ratio is 60% vs. 12%, the carbohydrate amount per day is 210 g vs. 42 g. This difference in carbohydrate intake possibly leads to lowering of blood glucose and lowering of CPR in urine, with mutual correlation.

Average glucose decreased in group 1 from day 2 to day 4, but the M value did not decrease. The reason would be that the M value is calculated with the absolute value of blood glucose away from 120 mg / dL, which is ideal blood glucose level.

Actually, several cases in group 1 showed almost normal range of blood glucose at day 2. These cases developed decreased blood glucose around 80-100 mg/L at day 4. That is why M value in group 1 did not decrease from day 2 to day 4 [32,33].

In the protocol of this study, diet therapy was changed from CR to LCD for T2DM. Among them, the main investigation were u-CPR measurements in 2 days apart, and it was possible to analyze the relationship with mean blood sugar and M value simultaneously. As a result, the reduction in carbohydrate intake decreased blood glucose level and glucose fluctuation, especially leading to a drastic decrease in M value.

In addition, insulin secretion was suppressed due to a decrease in blood glucose spike, leading to decreased u-CPR excretion which is an indicator of insulin secretion. From the above, it can be said that the series of pathophysiological pathway in diabetes has been improved in the short term. These results suggest that LCD would have remarkable efficacy for nutritional treatment of diabetes.

Significant correlation between blood glucose in average and HbA1c ($p < 0.01$) was observed. Its regression curve would indicate that $HbA1c (\%) = 0.02 \times AG (mg/dL) + 4.2$. When x axis and y axis changes each other, the equation becomes " $AG = 25.3 \times HbA1c - 12.2$ ".

Well-known equation has been reported by Nathan et al. which was " $AG = 28.7 \times HbA1c - 46.7$ " analyzed from 2700 samples [34]. As a comparison, substitute HbA 1 c = 7, 8, 9% into our formula and Nathan's formula. Then, the result is 165.1 vs 154.2 mg / dL, 190.2 vs 182.9 mg / dL, 215.5 vs 211.6 mg / dL, and both estimated values are near and compatible.

We measured average blood glucose 7 times a day. It is said that the difference from the measurement of 20 times



in the past is small and that the reliability is actually high. The subjects in this research were 84 cases of type 2 diabetes, including cases where HbA1c was low. Several cases in group 1 may showed lower HbA1c and blood glucose may be a higher than that of normal subjects which has the same HbA1c level.

On the other hand, study by Nathan et al. included type 1 diabetes, type 2 diabetes and normal individuals. Therefore, in regions where HbA1c is low, blood sugar levels are expected to be lower because there are many samples of normal subjects. Actually, if we enter 6% as HbA1c level into both formulas of ours and Nathan, data would be 139.6 mg/dL vs 125.5 mg/dL.

U-CPR has been a simple and useful test in the diagnosis of diabetes [35]. It has been said that u-CPR and serum CPR has been said to be highly correlated [36]. Recently, measurement of u-CPR with creatinine would be recommended for more accurate result [37,38].

C-peptide is clinically simple, noninvasive and useful examination for diabetes. Its application would be spreading in various situation, such as outpatient, in-patients and postprandial measurements [39-41].

Conclusion

In this study, we reported the changes in average glucose, M value and urine CPR value after meal change from CR to LCD. Associated with several correlation among them, and our results would become basic data for pathophysiological analysis of glucose metabolism of future research.

Acknowledgement

The part of the content of this article was presented at the 90th Scientific Meeting of Japan Endocrine Society (JES) Annual Congress, Kyoto, 2017. The authors would like to thank the patients and staffs for their cooperation and support.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

- 1) van Wyk HJ, Davis RE, Davies JS. A critical review of low-carbohydrate diets in people with Type 2 diabetes (2016) *Diabet Med* 33: 148-157.
- 2) Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes (2017) *BMJ Open Diabetes Res Care* 5: e000354.
- 3) Namazi N, Larijani B, Azadbakht L. Low-Carbohydrate-Diet Score and its Association with the Risk of Diabetes: A Systematic Review and Meta-Analysis of Cohort Studies (2017) *Horm Metab Res* 49: 565-571.
- 4) Atkins R. Dr. Atkins' new diet revolution, Rev edn (1998) Avon books, New York, USA.
- 5) Bernstein RK. Dr. Bernstein's Diabetes solution: The Complete Guide to Achieving Normal Blood Sugars (2007) Little, Brown US, New York, USA.
- 6) Accurso A, Bernstein RK, Dahlqvist A, Draznin B, Feinman RD, Fine EJ et al. Dietary carbohydrate restriction

in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal (2008) *Nutr Metab (Lond)* 5: 9.

7) Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, et al. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet (2008) *N Engl J Med* 359: 229-241.

8) Schwarzfuchs D, Golan R, Shai I. Four-year follow-up after two-year dietary interventions (2012) *N Engl J Med* 367: 1373-1374.

9) Atallah R, Filion KB, Wakil SM, Genest J, Joseph L, et al. Long-Term Effects of 4 Popular Diets on Weight Loss and Cardiovascular Risk Factors: A Systematic Review of Randomized Controlled Trials (2014) *Circ Cardiovasc Qual Outcomes* 7: 815-827.

10) Hashimoto Y, Fukuda T, Oyabu C, Tanaka M, Asano M, et al. Impact of low-carbohydrate diet on body composition: meta-analysis of randomized controlled studies (2016) *Obes Rev* 17: 499-509.

11) Haghghatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L. The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials (2016) *J Res Med Sci* 21: 53.

12) Tokuchi Y, Nakamura Y, Munekata Y, Tokuchi F. Low carbohydrate diet-based intervention for obstructive sleep apnea and primary hypothyroidism in an obese Japanese man (2016) *Asia Pac Fam Med* 15: 4.

13) Ebe K, Ebe Y, Yokota S, Matsumoto T, Hashimoto M, et al. Low Carbohydrate diet (LCD) treated for three cases as diabetic diet therapy (2004) *Kyoto Medical Association Journal* 51: 125-129.

14) Bando H, Nakamura T. Carbo-count therapy and low carbohydrate diet (LCD) (2008) *The Journal of the Therapy* 90: 3105-3111.

15) Bando H, Ebe K, Nakamura T, Bando M, Yonei Y. Low Carbohydrate Diet (LCD): Long and short-term effects and hyperketonemia (2016) *Glycative Stress Research* 3: 193-204.

16) Muneta T, Kawaguchi E, Nagai Y, Matsumoto M, Ebe K, et al. Ketone body elevation in placenta, umbilical cord, newborn and mother in normal delivery (2016) *Glycative Stress Research* 3: 133-140.

17) Bando H, Ebe K, Sakamoto K, Ogawa T, Bando M, et al. Remarkable Weight Reduction for Low Carbohydrate Diet (LCD): Case Report (2017) *Diabetes Case Rep* 2: 130.

18) Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Effect of low carbohydrate diet on type 2 diabetic patients and usefulness of M-value (2017) *Diabetes Res Open J* 3: 9-16.

19) Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetics (1965) *Acta Med Scand* 177: 95-102.

20) Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability (1970) *Diabetes* 19: 644-655

21) Moberg E, Kollind M, Lins PE, Adamson U. Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus (1993) *Scand J Clin Lab Invest* 53: 507-514

22) Siegelaar SE, Holleman F, Hoekstra JBL, Devries JH. Glucose Variability; Does It Matter? (2010) *Endocrine Reviews* 31: 171-182.

Citation: Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Urinary C-Peptide Excretion for Diabetic Treatment in Low Carbohydrate Diet (LCD) (2018) *Journal of Obesity and Diabetes* 1: 13-18.



- 23) Monnier L, Colette C. Glycemic Variability: Can We Bridge the Divide Between Controversies? (2011) *Diabetes Care* 34: 1058-1059.
- 24) McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ; A novel approach to continuous glucose analysis utilizing glycemic variation (2005) *Diabetes Technol Ther* 7: 253-263.
- 25) Yanai H. Four step excel statistics, 4th Edition (2015) Seiun-sha Publishing Co.Ltd, Tokyo, Japan.
- 26) Nakamura Y, Okuda N, Okamura T, Kadota A, Miyagawa N, et al. Low-carbohydrate diets and cardiovascular and total mortality in Japanese: a 29-year follow-up of NIPPON DATA80 (2014) *Br J Nutr* 112: 916-924.
- 27) Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base (2015) *Nutrition* 31: 1-13.
- 28) Meng Y, Bai H, Wang S, Li Z, Wang Q, Chen L. Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: A systematic review and meta-analysis of randomized controlled trials (2017) *Diabetes Res Clin Pract* 131: 124-131.
- 29) Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Proposal for Insulinogenic Index (IGI)-Carbo70 as Experimental Evaluation for Diabetes (2017) *J Clin Exp Endocrinol* 1: 102.
- 30) Ebe K, Bando H, Yamamoto K, Bando M, Yonei Y. Daily carbohydrate intake correlates with HbA1c in low carbohydrate diet (LCD). (2018) *J Diabetol* 1: 4-9.
- 31) Bando H, Ebe K, Muneta T, Bando M, Yonei Y. Investigation of uric acid and cystatin C on low-carbohydrate diet (LCD) (2017) *Diabetes Res Open J* 3: 31-38.
- 32) Service FH. Glucose variability (2013) *Diabetes* 62: 1398-1404.
- 33) Baghurst P. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm (2011) *Diabetes Technol Ther* 13: 296-302.
- 34) Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, et al. A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values (2008) *Diabetes Care* 31: 1473-1478.
- 35) Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabet Med*. 2013;30(7):803-17. doi: 10.1111/dme.12159.
- 36) Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide (1991) *Diabetes Res Clin Pract*.14: 165-173.
- 37) Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes (2011) *Diabet Med* 29: 90-93.
- 38) Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes (2011) *Diabetes Care* 34: 607-609.
- 39) McDonald TJ, Perry MH. Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function (2016) *Methods Mol Bio* 1433: 93-102.
- 40) Sonoda R, Tanaka K, Kikuchi T, Onishi Y, Takao T, Tahara T, et al. C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus (2016) *PLoS One* 11: e0147303.
- 41) Saisho Y. Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes (2016) *Int J Mol Sci* 17: E744.